Results 61 to 70 of about 2,720 (166)

Cefmetazole Resistance Mechanism for Escherichia Coli Including ESBL-Producing Strains

Infection and Drug Resistance, 2022
Ryota Ito, Masato Kawamura, Takumi Sato, Shigeru Fujimura Tohoku Medical and Pharmaceutical University, Division of Clinical Infectious Diseases & Chemotherapy, Sendai, Miyagi, JapanCorrespondence: Ryota Ito, Tohoku Medical and Pharmaceutical University,
Ito R, Kawamura M, Sato T, Fujimura S
doaj  

Rectal Carriage of Sequence Type 307 Klebsiella pneumoniae High‐Risk Clone Harboring Multiple Carbapenemase Genes in Community Hospitals Gauteng, South Africa

MicrobiologyOpen, Volume 14, Issue 6, December 2025.
Graphical presentation of rectal carriage of carbapenem‐resistant Klebsiella pneumoniae, highlighting ST307 high‐risk clone and IncX3 plasmid‐associated blaOXA‐181. This study highlights the threat linked to horizontal gene transfer of AMR genes by epidemic plasmids from Klebsiella pneumoniae high‐risk clones to other bacterial species.
Kafilat Taiwo Salvador‐Oke, Johann Pitout, Gisele Peirano, Kathy‐Anne Strydom, Chanel Kingsburgh, Marthie Ehlers, Marleen Kock   +6 more
wiley   +1 more source

Various Bacillus and Paenibacillus Spp. Isolated From Soil Produce Compounds With Potent Antimicrobial Activity Against Clinically Relevant Pathogens

MicrobiologyOpen, Volume 14, Issue 6, December 2025.
This study identified soil‐derived Bacillus and Paenibacillus strains with broad‐spectrum antimicrobial activity, including 97% inhibition of CREs by Paenibacillus profundus. Genome mining revealed biosynthetic gene clusters (NRPSs, PKSs, RiPPs) linked to antimicrobial production, highlighting their potential in combating antibiotic resistance. Created
Michael Moran, Hogan Turner, Joseph Yanchar, Joshua Preece, Gene Ahlborn, Richard Robison   +5 more
wiley   +1 more source

Aztreonam Combinations with Avibactam, Relebactam, and Vaborbactam as Treatment for New Delhi Metallo-β-Lactamase-Producing Enterobacterales Infections—In Vitro Susceptibility Testing

Pharmaceuticals
Antimicrobial resistance is a major global health issue. Metallo-β-lactamases (MBL), in particular, are problematic because they can inactivate all classes of β-lactams except aztreonam.
Małgorzata Brauncajs, Filip Bielec, Marlena Malinowska, Dorota Pastuszak-Lewandoska   +3 more
doaj   +1 more source

Mechanistic basis for inhibition of the extended‐spectrum β‐lactamase GES‐1 by enmetazobactam and tazobactam

FEBS Letters, Volume 599, Issue 22, Page 3284-3300, November 2025.
Antimicrobial resistance (AMR) is of huge importance, resulting in over 1 million deaths each year. Here, we describe how a new drug, enmetazobactam, designed to help fight resistant bacterial diseases, inhibits a key enzyme (GES‐1) responsible for AMR. Our data show it is a more potent inhibitor than the related tazobactam, with high‐level computation
Michael Beer, Philip Hinchliffe, Marko Hanževački, Christopher R. Bethel, Catherine L. Tooke, Marc W. Van der Kamp, Krisztina M. Papp‐Wallace, Robert A. Bonomo, Stuart Shapiro, Adrian J. Mulholland, James Spencer   +10 more
wiley   +1 more source

Antibiotic Resistance: A Genetic and Physiological Perspective

MedComm, Volume 6, Issue 11, November 2025.
The development of resistance to antimicrobials and their historical progression are depicted in this graphic. It draws attention to important biochemical, physiological, and genetic factors that contribute to AMR, such as the transmission of genes, the development of biofilms, and the inactivation of antibiotics.
Rania G. Elbaiomy, Ahmed H. El‐Sappah, Rong Guo, Xiaoling Luo, Shiyuan Deng, Meifang Du, Xiaohong Jian, Mohammed Bakeer, Zaixin Li, Zhi Zhang   +9 more
wiley   +1 more source

Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach.

PLoS ONE, 2020
Imipenem/cilastatin/relebactam is a β-lactam/β-lactamase inhibitor that has been recently FDA approved for complicated intra-abdominal and urinary tract infections under the brand name Recarbrio®.
Islam M Ghazi, Wasim S El Nekidy, Regan Asay, Paul Fimognari, Anthony Knarr, Mina Awad   +5 more
doaj   +1 more source

Chronic Pulmonary Aspergillosis Secondary Infection: A Case Report of Achromobacter spp. Lung Infection

Clinical Case Reports, Volume 13, Issue 10, October 2025.
ABSTRACT Both pulmonary tuberculosis (PTB) and coronavirus disease‐2019 (COVID‐19) are risk factors for chronic pulmonary aspergillosis (CPA) and other pulmonary infectious diseases because of residual lung damage. We report a case of Achromobacter spp. infection following CPA in an immunocompetent woman with a history of PTB and COVID‐19.
Marius Paulin Ngouanom Kuate, Felix Bongomin, David W. Denning   +2 more
wiley   +1 more source

Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence

Life
(1) Background: Infections caused by multidrug-resistant (MDR) bacteria represent one of the major global public health problems of the 21st century. Beta-lactam antibacterial agents are commonly used to treat infections due to Gram-negative pathogens. New β-lactam/β-lactamase inhibitor combinations are urgently needed.
Sansone, Pasquale, Giaccari, Luca Gregorio, Di Flumeri, Giusy, Pace, Maria Caterina, Pota, Vincenzo, Coppolino, Francesco, Brunetti, Simona, Aurilio, Caterina   +7 more
openaire   +4 more sources

Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam

Microbiology Spectrum
With the introduction of ceftazidime-avibactam worldwide, the antimicrobial activity of new β-lactam/β-lactamase inhibitors (BL/BLIs) needs to be investigated.
Min Seo Kang, Jin Yang Baek, Jae-Hoon Ko, Sun Young Cho, Keon Young Lee, Young Ho Lee, Jinyoung Yang, Tae Yeul Kim, Hee Jae Huh, Nam Yong Lee, Kyungmin Huh, Cheol-In Kang, Doo Ryeon Chung, Kyong Ran Peck   +13 more
doaj   +1 more source